ELEVANCE HEALTH INC

Elevance Health stays a core value pick in Baupost’s portfolio while leading the real‑world evidence (RWE) shift, pairing AI analytics with digital health to fuel value‑based care and future regulatory approvals.

Explore ELEVANCE Health’s latest SEC filing: 10b5‑1 share sales reveal a disciplined, low‑volatility strategy amid strong data‑analytics growth and regulatory focus.

Australian equity market sees health‑care index shift toward defensive play, with ELEVANCE HEALTH INC’s growth focus hit by higher RBA rates and weaker housing.

Elevance Health declares a $1.72 per‑share dividend, yielding 1.68%, showing financial strength amid rising Treasury yields and offering modest income for investors.

Elevance Health’s senior executives sold vested RSU shares to cover taxes, keeping ownership and governance steady – a routine move reflecting standard industry practice.

Elevance Health’s Form 4 filings show routine executive RSU tax‑withholding sales at market price, confirming transparent governance and compliance.

Elevance Health teams with HABRI and Airvet to turn pet‑ownership into an employer‑level wellness KPI, unlocking data‑driven benefits and new revenue streams.

ASX 200 dips as RBA rate‑hike expectations rise; Ramsay Health leads the healthcare sector, while ELEVANCE HEALTH remains flat but poised for value‑based growth amid shifting reimbursement models.

SEC Form 4 reveals ELEVANCE HEALTH’s share gift to a trust, reducing owner influence while keeping board continuity—and highlights ELEV‑01’s promising 42% response rate.

AN2 Therapeutics’ insider gift to a trust signals possible restructuring and future funding plans, while Ashok Leyland’s 12 % revenue jump and premium‑EV push reveal a strategic pivot toward higher‑margin, sustainable commercial vehicles.